NVS Stock Recent News

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

If there were an official hierarchy of qualities that dividend seekers should consider before investing in a stock, a company's underlying business would almost certainly come ahead of its yield. However, the two aren't mutually exclusive.

Novartis CEO Vas Narasimhan weighs in on the impact of the new U.S. administration and artificial intelligence on the pharmaceutical industry, as well as the possibility of further acquisitions.

NVS' fourth-quarter earnings and sales beat estimates. Based on the strong momentum of the company?

Novartis AG (NVS) Q4 2024 Earnings Call Transcript

Although the revenue and EPS for Novartis (NVS) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Swiss pharmaceutical giant Novartis on Friday reported better-than-expected sales in the fourth quarter, but falling short of its own guidance over the full-year stretch. Fourth-quarter net sales rose 16% on a constant currency basis to $13.2 billion, compared to the $12.795 billion estimated by analysts in an LSEG poll.

The American CEO of Swiss drugmaker Novartis on Friday warned that the United States' exit from the World Health Organization and related programmes risks harming millions of people worldwide.

Novartis on Friday posted quarterly adjusted net income well above analyst estimates on higher drug revenues.

Ad hoc announcement pursuant to Art. 53 LR Full year Net sales grew +12% (cc 1 , +11% USD) with core operating income 1 up +22% (cc, +19% USD) Sales growth driven by continued strong performance from Entresto (+31% cc), Cosentyx (+25% cc), Kesimpta (+49% cc), Kisqali (+49% cc), Pluvicto (+42% cc) and Leqvio (+114% cc) Core operating income margin1 38.7%, +330 basis points (cc), mainly driven by higher net sales Operating income grew +55% (cc, +49% USD); net income up +45% (cc, +39% USD) Core EPS 1 grew +24% (cc, +21% USD) to USD 7.81 Free cash flow 1 of USD 16.3 billion (+24% USD) driven by higher net cash flows from operating activities Fourth quarter Net sales grew +16% (cc, +15% USD) with core operating income up +29% (cc, +27% USD) Sales growth driven by continued strong performance from Entresto (+34% cc), Kesimpta (+49% cc), Kisqali (+52% cc), Cosentyx (+24% cc), and Leqvio (+83% cc) Selected innovation milestones: Scemblix FDA accelerated approval for 1L Ph+ CML-CP Kisqali EC ap